Mitsumori Kenji, Kittleson John M, Itoh Noriyuki, Delahunt Brett, Heathcott Rosemary W, Stewart John H, McCredie Margaret R E, Reeve Anthony E
Department of Biochemistry, University of Otago, Dunedin, New Zealand.
J Pathol. 2002 Sep;198(1):110-4. doi: 10.1002/path.1165.
The progression of a malignant tumour is understood to be the result of the accumulation of multiple genetic aberrations. As up to 14% of organ-confined renal cell carcinomas will recur after surgery, tumour clones with metastatic potential must already be present in some of these localized tumours. The association of 14q LOH with high-grade tumours and advanced tumour stage suggests an important role for the gene in tumour progression. Chromosome 14q LOH has been analysed in microdissected specimens from 130 organ-confined (UICC TNM stage 1 and 2) clear cell renal cell carcinomas using three microsatellite markers (D14S588, D14S617, GATA136B01). Tumours were classified as 14q LOH or not on the basis of LOH at one or more of the markers. The allelic imbalance ratio was used to determine both LOH and LOH proportion and the association between LOH and mortality, tumour size, histological grade and growth kinetics, measured by quantification of nucleolar organizer regions, was analysed. 14q LOH was present in 35.4% of informative cases at marker D14S588, 24.4% at D14S617, 36.4% at GATA136B01 and 39.5% for any one of the three markers. The mean 14q LOH proportion was 0.24 (range 0.009-0.80). LOH proportion correlated significantly with tumour size, AgNOR score and histological grade. It was also significantly associated with disease-specific mortality; (hazard ratio 1.22; 95% CI 1.02-1.45; p = 0.039). LOH proportion did not remain significant after adjusting for tumour size (hazard ratio 0.98; 95% CI 0.76-1.27; p = 0.90). These results indicate that the proportion of cells with 14q LOH in the tumour is associated with tumour aggressiveness; while this is not an independent predictor of survival, it may have some utility as a marker of latent metastatic potential.
恶性肿瘤的进展被认为是多种基因畸变积累的结果。由于高达14%的器官局限性肾细胞癌在手术后会复发,因此在这些局限性肿瘤中,某些肿瘤必定已经存在具有转移潜能的克隆。14号染色体长臂杂合性缺失(14q LOH)与高级别肿瘤及肿瘤晚期相关,提示该基因在肿瘤进展中起重要作用。本研究采用3个微卫星标记(D14S588、D14S617、GATA136B01),对130例器官局限性(国际抗癌联盟TNM分期1期和2期)透明细胞肾细胞癌的显微切割标本进行14号染色体长臂杂合性缺失分析。根据一个或多个标记的杂合性缺失情况,将肿瘤分为14q LOH或无14q LOH。采用等位基因失衡率确定杂合性缺失及其比例,并分析杂合性缺失与死亡率、肿瘤大小、组织学分级以及通过核仁组织区定量测定的生长动力学之间的关系。在标记D14S588处,35.4%的信息性病例存在14q LOH;在D14S617处为24.4%;在GATA136B01处为36.4%;三个标记中任何一个出现杂合性缺失的比例为39.5%。14q LOH的平均比例为0.24(范围0.009 - 0.80)。杂合性缺失比例与肿瘤大小、核仁组成区嗜银蛋白(AgNOR)评分及组织学分级显著相关。它还与疾病特异性死亡率显著相关(风险比1.22;95%可信区间1.02 - 1.45;p = 0.039)。在对肿瘤大小进行校正后,杂合性缺失比例不再具有显著性(风险比0.98;95%可信区间0.76 - 1.27;p = 0.90)。这些结果表明,肿瘤中存在14q LOH的细胞比例与肿瘤侵袭性相关;虽然这不是生存的独立预测指标,但它可能作为潜在转移潜能的标志物具有一定用途。